PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Leora Horn, MD, MSc, FRCPC - The Present and Future of Immunotherapy as a Key Component of the Treatment Arsenal for Locally Advanced & Earlier Stages of Lung Cancer

Richard S. Finn, MD / Laura M. Kulik, MD - Rethinking Care in Hepatocellular Carcinoma Amid Expanding Treatment Options: An Interdisciplinary Discussion

Robert Anders, MD, PhD - Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Implications for Pathologists at the Forefront of the Emerging Precision Immuno-Oncology Era

Amy Goodrich, NP - Oncology Nurse Insights Into New Agent Classes and Research in B-Cell Lymphoma: Practical Issues and Evidence for the Front-Lines of Care

Amir T. Fathi, MD - The Oncologist, Nurse, and Patient Partnership in AML: Multiple Perspectives on Integrating Targeted Therapy Into Care

Edward B. Garon, MD, MS - Improving Patient Outcomes With Cancer Immunotherapies Throughout the Lung Cancer Continuum: State of the Science and Implications for Practice

Anjali Saqi, MD, MBA and Geoffrey R. Oxnard, MD - Navigating the Complexities of Molecular Testing for EGFR Mutations to Guide Treatment Selection in Lung Cancer: Evidence, Practicalities, and Implications for Pathologists

Kurt Schalper, MD, PhD and Edward B. Garon, MD, MS - Advances and Challenges in Refining the Use of Cancer Immunotherapies Through Biomarker Testing: Practical Guidance for Pathologists on the Front Lines of the Immuno-Oncology Revolution

Lynette M. Sholl, MD - Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do

Roy H. Decker, MD, PhD - The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition Into the Multimodal Treatment Arsenal

Justin F. Gainor, MD - New Frontiers in Precision Immuno-Oncology: Leveraging Biomarkers to Refine and Expand the Use of Cancer Immunotherapies and Combinations

Jason J. Luke, MD, FACP and Jennifer Wargo, MD, MMSc - Progress and Promise With Immunotherapy in Resectable Melanoma: Exploring New Evidence and Practical Issues With Checkpoint Inhibitors as Adjuvant Therapy

Benjamin Levy, MD - Refining Current Practice and Exploring New Frontiers in EGFR-Mutant NSCLC: Evolving Science, New Standards of Care, and Implications for Multidisciplinary Management

Sagar Lonial, MD, FACP - Innovative Therapeutic Concepts for ASCT-Eligible Patients With Myeloma: Advancing Toward More Effective Care Across Treatment Settings

Mitchell S. Cairo, MD - Attacking the Clinical Problem of VOD/SOS in HCT Recipients: Insights on Pathophysiology, Diagnosis, and Treatment

Tanya Siddiqi, MD - Harnessing Recent Advances in CAR-T Cell Therapy for Leukemia and Lymphoma in the Era of Stem Cell Transplantation

Leonard H. Calabrese, DO - Rheumatology, Immunology, and Immuno-Oncology Intersect: Navigating the Complexities of Immune Checkpoint Inhibition, Autoimmunity, and Immune-Related Adverse Events: How Can Rheumatologists Help Minimize the Risks and Maximize the Benefits of Cancer Immunotherapies?

Mark A. Socinski, MD - Expanding Options and Difficult Choices in the Initial Treatment of Advanced NSCLC: How to Personalize Treatment Decisions in the Era of Immuno-Oncology and Combinations

Alexander Perl, MD and James M. Foran, MD, FRCPC - Integrating Innovative Therapeutics With Allogeneic HCT in AML: Insights and Evidence From Induction to Maintenance

Madan H. Jagasia, MBBS, MS, MMHC - Innovative Therapies in Post-Transplant GVHD: Personal Insights From the Patient CaseBook